PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930155
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930155
The global anti-snoring devices market is witnessing significant growth, driven by the rising prevalence of sleep disorders and increasing awareness about the health impacts of snoring. The market was valued at USD 1.15 billion in 2025 and is projected to grow to USD 1.14 billion in 2026, reaching USD 2 billion by 2032, reflecting a CAGR of 7.40% over the forecast period. North America dominated the market in 2025 with a 37.88% share, primarily due to high prevalence of obstructive sleep apnea (OSA) and a large population of regular snorers.
Anti-snoring devices are non-invasive solutions that help reduce or prevent snoring by keeping the airway open during sleep. These devices include mandibular advancement devices (MADs), tongue retaining devices (TRDs), chin straps, and nasal dilators, which are also effective in managing mild to moderate OSA. The increasing penetration of over-the-counter anti-snoring devices is further supporting market growth globally.
The market is led by major players such as ResMed, Fisher & Paykel Healthcare Limited, and SomnoMed, who hold a strong global presence and a diversified product portfolio.
Market Dynamics
Market Drivers
The rising prevalence of sleep disorders such as snoring and obstructive sleep apnea is a key driver for anti-snoring devices. Globally, an estimated 936 million adults aged 30-69 have mild to severe OSA, increasing the demand for non-invasive, affordable, and comfortable treatment solutions. Anti-snoring devices offer an effective alternative to airway pressure therapy and surgical interventions, which are often invasive and expensive. Technological innovations that improve comfort, efficacy, and patient compliance further drive adoption.
Market Restraints
Despite growth, the market faces challenges due to limited consumer awareness and adoption. Many individuals are unaware that snoring is a medical condition requiring intervention. Misconceptions regarding discomfort or inefficacy also restrict acceptance. Additionally, the lack of diagnostic facilities and limited knowledge in developing countries hinder market penetration. For example, 40.3% of U.S. adults diagnosed with sleep apnea had not tried any treatment as of 2023.
Market Opportunities
Emerging markets present significant opportunities for anti-snoring device manufacturers. Rising disposable incomes, improved healthcare awareness, and better diagnostic facilities in regions such as Asia Pacific, Latin America, and parts of Africa are fueling demand. Companies are leveraging localized awareness campaigns, strategic partnerships with healthcare providers, and affordable product lines to expand market reach and increase adoption.
Market Challenges
Competition from positive airway pressure (PAP) therapy devices and surgical interventions such as Uvulopalatopharyngoplasty (UPPP) or radiofrequency ablation poses challenges. PAP devices are often prescribed by healthcare professionals and covered by insurance, making them a preferred choice for moderate to severe OSA patients. Surgical interventions offer long-term relief, reducing reliance on over-the-counter devices. In the U.S., there were around 18,526 surgical encounters for OSA in 2019, reflecting strong preference for clinical treatments.
Market Trends
Non-invasive and tech-driven solutions are key market trends. Smart devices incorporating sensors, AI, and Bluetooth connectivity enable personalized treatment plans, real-time monitoring, and integration with mobile apps. Devices like ProSomnus' EVO [PH], FDA-cleared in 2022, offer jaw adjustment during sleep, enhancing comfort and compliance. Remote diagnosis through telemedicine and wearable technology integration are expanding the market and attracting health-conscious consumers.
By Device Type:
By Distribution Channel:
North America: Dominated the market in 2025 with USD 0.4 billion, projected to reach USD 0.43 billion in 2026. The U.S. alone is estimated to account for USD 0.41 billion in 2026 due to high snoring prevalence and treatment rates.
Europe: Projected to grow at a 7.4% CAGR, reaching USD 0.32 billion in 2026, supported by established supply chains and key players. The U.K., Germany, and France are major contributors.
Asia Pacific: Estimated at USD 0.28 billion in 2026, with India and China contributing USD 0.04 billion and 0.11 billion, respectively. Growth is driven by rising awareness and improving healthcare infrastructure.
Latin America: Expected to reach USD 0.07 billion in 2026, with increased awareness among OSA patients.
Middle East & Africa: GCC countries expected to reach USD 0.02 billion in 2025.
Competitive Landscape
Major players include SomnoMed (Australia), ResMed (U.S.), Glidewell (U.S.), Panthera Dental (Canada), Fisher & Paykel Healthcare (New Zealand), ProSomnus Sleep Technologies (U.S.), and others. Companies focus on product innovation, geographic expansion, and awareness campaigns. Strategic collaborations, like Rotech Healthcare and Signifier Medical partnership in 2024, strengthen distribution and product accessibility.
Conclusion
The global anti-snoring devices market is projected to grow from USD 1.15 billion in 2025 to USD 2 billion by 2032, at a CAGR of 7.40%. Growth is fueled by the rising prevalence of sleep disorders, technological innovations in smart and non-invasive devices, and expanding awareness in emerging markets. While challenges remain from limited consumer adoption and competition from PAP therapy and surgical solutions, market opportunities in developing regions and technological advancements position the anti-snoring devices market for sustained growth through 2032.
Segmentation By Device Type, Distribution Channel, and Region
By Device Type * Mandibular Advancement Devices
By Distribution Channel * Hospital Pharmacies
By Geography * North America (By Device Type, Distribution Channel, and Country)